How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind
Just how much is your vision worth?
That’s the billion-dollar question at Spark Therapeutics now as the FDA winds up with an odds-on approval for its gene therapy used to fix a rare form of inherited blindness called RPE65-mediated retinal dystrophy.
It’s verboten in biopharma for CEOs to discuss hard prices ahead of an approval, but Spark $ONCE CEO Jeff Marrazzo has been doing the math on the economic value of vision, and came up with a substantial 7-figure number: $1 million-plus for Luxturna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.